Another Positive Phase III For Lilly's, Incyte's Baricitinib
This article was originally published in Scrip
Eli Lilly & Co. and Incyte Corp. reported on Sept. 29 that baricitinib bested the first-line rheumatoid arthritis (RA) standard of care methotrexate in a late-stage clinical trial, so now the partners must complete just one more Phase III trial before seeking regulatory approvals for the JAK inhibitor.
You may also be interested in...
During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.
The strategy for both funds is to back companies with a preclinical drug candidate that can be advanced through clinical proof-of-concept with a mid-sized series A round.
Three firms launched initial public offerings during the first week of May, but Gyroscope postponed its IPO while Jasper, Science 37 and Roivant took the special purpose acquisition corporation route.